Telangana targets Rs 1 lakh crore investments in Life Sciences by 2030

Telangana has set an ambitious target of attracting Rs 1 lakh crore in new investments in the Life Sciences sector by 2030, aiming to generate employment for five lakh people, said Minister for IT and Industries Duddilla Sridhar Babu.

Delivering the keynote address at the AusBiotech International Conference 2025 in Melbourne (being held from 21 to 24 October 2025) — organised jointly by AusBiotech and the Government of Victoria - the Minister said the State government has drawn up a comprehensive “Roadmap 2030” to position Telangana as a Global Life Sciences Hub. “Telangana is preparing a Comprehensive Life Sciences Policy to accelerate innovation, infrastructure, and global partnerships,” Sridhar Babu said, outlining the State’s strategy for the next phase of bio-digital growth.

The Minister said Telangana continues to outperform national averages in economic growth. Though the State ranks 11th in geographical area and 12th in population, it contributes over 5% to India’s GDP. Telangana’s GSDP growth rate in 2024–25 stood at 8.2%, compared with the national average of 7.6%, he noted. Over the past 20 months, the State has attracted Rs 3.2 lakh crore in new investments, with Rs 63,000 crore coming from the Life Sciences sector alone. Exports from the sector crossed Rs 26,000 crore between April and December 2024. The State aims to increase the value of the Life Sciences economy from $80 billion to $250 billion by 2030, the Minister said.

Citing a report by global consultancy CBRE, Sridhar Babu said Hyderabad has been featured in the Global Life Sciences Atlas 2025 among the world’s leading Life Sciences clusters — alongside Boston, San Francisco, Cambridge, Beijing, and Tokyo. Hyderabad is the only Indian city to feature in this list, he added. Life Sciences office leasing in the city expanded from 0.6 million sq. ft. in 2022 to 2.4 million sq. ft. in 2024, reflecting the sector’s rapid growth and investor confidence.

Sridhar Babu invited Australian companies to explore investment opportunities in emerging and high-growth areas such as Cell and Gene Therapy, Biologics and Biosimilars, mRNA Vaccines, Contract Research, Development and Manufacturing (CRDM), Diagnostics, MedTech, and Digital Health. He also highlighted Telangana’s focus on AI-based Drug Discovery, Genomics, Green Biomanufacturing, Agri-Biotech, and Animal Health, saying these sectors offer immense potential for collaboration and value creation.